8-K - Bicara Therapeutics Inc. Common Stock | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Bicara Therapeutics reported increased net losses for Q4 and full year 2025, selected an optimal dose for its pivotal Phase 3 trial, and expects its cash to fund operations into the first half of 2029.

Key Takeaways

1Net loss was $37.4 million for Q4 2025, compared to $21.0 million for Q4 2024.

2Net loss was $138.0 million for the full year 2025, compared to $68.0 million for the full year 2024.

3Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial.

4Expects substantial enrollment in the FORTIFI-HN01 pivotal study by the end of 2026 to enable an interim analysis readout in mid-2027.

5Cash, cash equivalents and marketable securities were $414.8 million as of December 31, 2025, with an expected cash runway into the first half of 2029.

6Raised net proceeds of $161.8 million through an oversubscribed public offering in the first quarter of 2026.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193

Financial Results

9.01

Financial Statements and Exhibits (d) The following exhibits are being filed herewith: Exhibit No.: 99.1 | Description: Press Release of Bicara Therapeutics Inc

Exhibits Only

Source Document

Results of Operations

Fourth Quarter 2025

Metric	Value	Prior Period
Research and Development Expenses	$33.00	$19.90
General and Administrative Expenses	$8.10	$6.80
Net Loss	$37.40	$21.00
Net Loss per share, basic and diluted	$0.68

Exhibits (2)

8-K

99.1

EX-99.1